Терапевтический архив (Jul 2017)

Use of crizotinib for refractory ALK-positive lymphomas

  • L N Shelikhova,
  • V V Fominykh,
  • D S Abramov,
  • N V Myakova,
  • M A Maschan,
  • A A Maschan

DOI
https://doi.org/10.17116/terarkh201789751-56
Journal volume & issue
Vol. 89, no. 7
pp. 51 – 56

Abstract

Read online

Aim. To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL). Subjects and methods. The paper describes the experience with crizotinib used in 8 patients with refractory ALK-ALCL before and after allogeneic hematopoietic stem cell transplantation (HSCT). Results. All the 8 (100%) patients treated with crizotinib were recorded to have complete responses, including complete metabolic ones (tumor disappearance as evidenced by positron emission tomography (PET)/computed tomography. Conclusion. Low and manageable toxicity of crizotinib and complete PET-negative responses in patients with resistant ALK lymphomas favor the need to test the drug as first-line therapy, by possibly decreasing the intensification of chemotherapy.

Keywords